Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.51 |
| ▸ | PDE4A | P27815 | 17/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73785 | 0.89 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL84964 | 0.86 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL8321734 | 0.86 | PDE4D (0.55) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL73163 | 0.86 | MKNK1 (0.46) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL8262616 | 0.83 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CGFER | |
| Hydrochloric Acid SCHEMBL72328 | 0.82 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL84499 | 0.81 | PDE4D (0.59) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL84495 | 0.80 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL85012 | 0.80 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4CGFER | |
| SCHEMBL3871482 | 0.77 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | PDE4D 11/4885PDE4A 3/4885PDE4B 6/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | PDE4D 10/4885PDE4A 3/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.